Can we change the disease biology of multiple myeloma?

Leukemia Research

Volumn 36, Issue SUPPL.1, 2012, Pages

  Borrello, Ivan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow microenvironment; Cell biology; Immunomodulatory drugs; Mode of action; Multiple myeloma; Proteosome inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LENALIDOMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PNEUMOCOCCUS VACCINE; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN C FOS; SOMATOMEDIN C; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSTIMULATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMNOLENCE; STROMA CELL; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM;

ANIMALS; BIOLOGY; BONE MARROW; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC DEFICIENCY SYNDROMES; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; TUMOR MICROENVIRONMENT;

EID: 84870039787     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/S0145-2126(12)70003-6     Document Type: Article

References (136)

1. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346(8):564-569.
2. Kyle RA, Kumar S The significance of monoclonal gammopathy of undetermined significance. Haematologica 2009, 94(12):1641-1644.
3. Kyle RA, Rajkumar SV Multiple myeloma. N Engl J Med 2004, 351(18):1860-1873.
4. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78(1):21-33.
5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
6. Turesson I, Velez R, Kristinsson SY, Landgren O Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010, 28(5):830-834.
7. Kumar SV, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79(7):867-874.
8. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103(6):2332-2336.
9. Huff CA, Matsui W Multiple myeloma cancer stem cells. J Clin Oncol 2008, 26(17):2895-2900.
10. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63(6):1424-1433.
11. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of " many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006, 91(9):1234-1240.
12. Grogan TM, Durie BG, Lomen C, Spier C, Wirt DP, Nagle R, et al. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood 1987, 70(4):932-942.
13. Cao J, Vescio RA, Rettig MB, Hong CH, Kim A, Lee JC, et al. A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers. Leukemia 1995, 9(11):1948-1953.
14. Kiel K, Cremer FW, Rottenburger C, Kallmeyer C, Ehrbrecht E, Atzberger A, et al. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 23(10):1019-1027.
15. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 1979, 150(4):792-807.
16. Epstein J, Xiao HQ, He XY Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 1990, 322(10):664-668.
17. Billadeau D, Ahmann G, Greipp P, Van Ness B The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993, 178(3):1023-1031.
18. Bakkus MH, Van Riet I, Van Camp B, Thielemans K Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994, 87(1):68-74.
19. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995, 155(5):2487-2497.
20. Svachova H, Pour L, Sana J, Kovarova L, Muthu Raja KR, Hajek R Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients. Leuk Res 2011, 35(8):1008-1013.
21. Pilarski LM, Belch AR Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994, 83(3):724-736.
22. Rottenburger C, Kiel K, Bösing T, Cremer FW, Moldenhauer G, Ho AD, et al. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 1999, 106(2):545-552.
23. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, International Myeloma Working Group, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23(12):2210-2221.
24. Seidl S, Kaufmann H, Drach J New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003, 4(9):557-564.
25. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997, 16(3):260-264.
26. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000, 95(3):992-998.
27. Martinez-Garcia E, Popovic R, Min D-J, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4; 14) multiple myeloma cells. Blood 2011, 117(1):211-220.
28. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109(8):3489-3495.
29. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002, 100(4):1417-1424.
30. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998, 91(12):4457-4463.
31. Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999, 24(1):9-15.
32. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101(11):4569-4575.
33. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006, 42(11):1564-1573.
34. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007, 101(4):950-968.
35. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007, 21(6):1007-1034. vii-viii.
36. Hideshima T, Anderson KC Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2(12):927-937.
37. Teoh G, Anderson KC Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11(1):27-42.
38. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87(3):1104-1112.
39. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82(12):3712-3720.
40. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003, 101(2):703-705.
41. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996, 2(11):1204-1210.
42. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69(3):1009-1015.
43. Azab AK, Quang P, Azab F, Magnani J, Patton J, Smith T, et al. Selectin inhibition disrupts multiple myeloma cells interaction with the bone marrow microenvironment and sensitizes them to therapy. Blood 2010, 116. [Abstract 453].
44. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15(12):1950-1961.
45. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95(8):2630-2636.
46. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89(1):227-234.
47. Löwik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1989, 162(3):1546-1552.
48. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20(33):4519-4527.
49. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999, 10(1):65-70.
50. Jöhrer K, Janke K, Krugmann J, Fiegl M, Greil R Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004, 10(6):1901-1910.
51. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, et al. CC-Chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008, 68(16):6840-6850.
52. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006, 66(13):6675-6682.
53. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007, 13(19):5903-5909.
54. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004, 103(8):3148-3157.
55. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996, 88(6):2250-2258.
56. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5(3):221-230.
57. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al. Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115(26):5385-5392.
58. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010, 116(18):3554-3563.
59. Cook G, Campbell JD Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev 1999, 13(3):151-162.
60. Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006, 47(8):1570-1582.
61. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004, 124(3):315-324.
62. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003, 197(12):1667-1676.
63. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100(1):230-237.
64. Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol 1998, 100(1):176-183.
65. Li J, Li M, Wang C, Wang J, Sanchez E, Li ZW, et al. Lack of binding of monocolonal protein produced by multiple meloma (MM) cells to FcγRIIb reduces immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling and provides the rationale for a novel therapeutic approach to MM. Blood 2010, 116. [Abstract 455].
66. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87(5):1928-1938.
67. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173(3):699-703.
68. D'Amato RJ, Loughnan MS, Flynn E, Folkman J Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91(9):4082-4085.
69. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98(1):210-216.
70. Haslett PAJ, Corral LG, Albert M, Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187(11):1885-1892.
71. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996, 39(17):3238-3240.
72. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999, 163(1):380-386.
73. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103(5):1787-1790.
74. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27(30):5008-5014.
75. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24(11):1934-1939.
76. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011, 118(11):2970-2975.
77. Leleu X, Attal M, Arnulf B, Duhamel A, Moreau P, Traulle C, et al. Phase 2 multicenter, randomized open label study of 2 modalities of pomalidomide plus low-dose dexamethasone (POMD) in patients with multiple myeloma (MM), refractory to both lenalidomide and bortezomib (double refractory). IFM 2009-02. Heamatologica 2011, 96(Suppl. 1):S72. [Abstract P-148].
78. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Jagannath S, Chen C, et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. Blood 2011, 118. [Abstract 634].
79. Zeldis JB, Knight RD, Jacques C, Tozer A, Bizzari JP Lenalidomide in multiple myeloma: current role and future directions. Expert Opin Pharmacother 2010, 11(5):829-842.
80. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327(5971):1345-1350.
81. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118(18):4771-4779.
82. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012 3 May, [Epub ahead of print].
83. Heintel D, Bolomsky A, Schreder M, Pfeifer S, Zojer N, Jäger U, et al. High expression of the thalidomide-binding protein cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Blood (ASH Annual Meeting Abstracts) 2011, 118. [Abstract 2879].
84. List AF Lenalidomide - the phoenix rises. N Engl J Med 2007, 357(21):2183-2186.
85. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154(3):325-336.
86. Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, et al. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117(19):5157-5165.
87. Huang X, Di Liberto M, Jayabalan D, Hussein M, Randolph S, Niesvizky R, et al. Lenalidomide targets myeloma cells preferentially during prolonged early G1 arrest but not synchronization into S phase by selective and reversible inhibition of CDK4/CDK6 through loss of IRF-4. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 449].
88. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69(18):7347-7356.
89. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10(2):155-167.
90. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99(12):4525-4530.
91. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96(9):2943-2950.
92. De Luisi A, Ferrucci A, Coluccia AML, Ria R, Moschetta M, de Luca E, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Can Res 2011, 17(7):1935-1946.
93. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24(1):22-32.
94. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87(3):503-508.
95. Vacca A, Di LM, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995, 50(1):9-14.
96. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87(10):1166-1172.
97. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005, 69(1-2):56-63.
98. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011, 117(17):4409-4419.
99. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22(10):1925-1932.
100. Terpos E, Christoulas D, Katodritou E, Kastritis E, Kyrtsonis MC, Papatheodorou A, et al. The effect of lenalidomide and dexamethasone combination on bone remodeling of relapsed/refractory myeloma: final results of two studies of the Greek Myeloma Study Group with 205 patients. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2):117. [Abstract 0283].
101. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol Exp Ther 2003, 305(3):1222-1232.
102. Haslett PAG, Hanekom WA, Muller G, Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003, 187(6):946-955.
103. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108(2):618-621.
104. Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010, 116(17):3227-3237.
105. Yamamoto M, Nishimoto N, Davydova J, Kishimoto T, Curiel DT Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells. Cancer Gene Ther 2006, 13(2):194-202.
106. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008, 140(1):36-45.
107. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14(14):4650-4657.
108. Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45(2):349-353.
109. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128(2):192-203.
110. Suh WK, Tafuri A, Berg-Brown NN, Shahinian A, Plyte S, Duncan GS, et al. The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28. J Immunol 2004, 172(10):5917-5923.
111. Baz R, Dimopoulos M, Richardson P, Yu Z, Hussein M, Chanan-Khan A Lenalaidomide-based thearapy leads to improvement of humoral immune system in relapsed or refractory mutliple myeloma patients who respond to the therapy. Haematologica 2009, 94(Suppl. 2):159. [Abstract 0395].
112. Noonan KA, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, et al. Lenalidomide augments immune responses to Prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines. Clin Cancer Res 2012, 18(5):1426-1434.
113. Myung J, Kim KB, Crews CM The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001, 21(4):245-273.
114. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteosome. Cancer Res 2007, 67(13):6383-6391.
115. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002, 99(22):14374-14379.
116. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
117. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9(3):1136-1144.
118. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 2009, 100(1):24-28.
119. Piazza F, Manni S, Brancalion A, Quotti Tubi L, Pavan L, Gurrieri C, et al. Inhibition of protein kinase CK2 enhances the cytotoxic effects of bortezomib on multiple myeloma cells. Hematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2):117. [Abstract 0284].
120. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101(6):2377-2380.
121. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66(1):184-191.
122. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007, 21(9):2025-2034.
123. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005, 131(1):71-73.
124. Lund T, Søe K, Abildgaard N, Garnero P, Pedersen PT, Ormstrup T, et al. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 2010, 85(4):290-299.
125. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111(11):1771-1782.
126. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66(14):7317-7325.
127. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008, 180(1):163-170.
128. Wang X, Ottosson A, Ji C, Feng X, Nordenskjöld M, Henter JI, et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009, 94(4):470-478.
129. Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, et al. Proteosome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 5021].
130. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107(9):3575-3583.
131. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grünebach F, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108(2):551-558.
132. Basler M, Lauer C, Beck U, Groettrup M The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009, 183(10):6145-6150.
133. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 2008, 124(2):234-246.
134. Dasanu CA, Alexandrescu DT Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?. J Oncol Pharm Pract 2010, 16(4):266-268.
135. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Inter-Groupe Francophone du Myélome (IFM), et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108(10):3289-3294.
136. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27(11):1788-1793.